Fifteen-S-Hydroxyeicosatetraenoic Acid (15-S-HETE) Specifically Antagonizes the Chemotactic Action and Glomerular Synthesis of Leukotriene B4 in the Rat
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Leukotriene D4induced Caco2 Cell Proliferation Is Mediated By
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Diposit Digital de la Universitat de Barcelona Physiological Reports ISSN 2051-817X ORIGINAL RESEARCH Leukotriene D4-induced Caco-2 cell proliferation is mediated by prostaglandin E2 synthesis Marisol Cabral, Raquel Martın-Venegas & Juan J. Moreno Departament de Fisiologia, Facultat de Farmacia, Universitat de Barcelona, Barcelona, Spain Keywords Abstract 5-lipoxygenase, arachidonic acid cascade, cell cycle, cell growth, colon cancer. Leukotriene D4 (LTD4) is a pro-inflammatory mediator formed from arachi- donic acid through the action of 5-lipoxygenase (5-LOX). Its biological effects Correspondence are mediated by at least two G-coupled plasmatic cysteinyl LT receptors (Cys- Juan Jose Moreno, Departament de LT1-2R). It has been reported an upregulation of the 5-LOX pathway in tumor Fisiologia, Facultat de Farmacia, Universitat tissue unlike in normal colon mucosa. Colon tumors generally have an de Barcelona, Avda. Joan XXIII s/n, 08028 increased expression of CysLT1R and colon cancer patients with high expres- Barcelona, Spain. sion levels of CysLT R have poor prognosis. We previously observed that the Tel: +34 93 402 4505 1 Fax: +34 93 403 5901 cyclooxygenase pathway is involved in the control of intestinal epithelial can- E-mail: [email protected] cer cell growth through PGE2 production. The aim of this study was therefore to assess the effect of LTD4 binding with CysLT1R on Caco-2 cell growth. We Funding Information note a number of key findings from this research. We observed that at a con- This research was supported by Spanish centration similar to that found under inflammatory conditions, LTD4 was Ministry of Science and Innovation (BFU2007- able to induce Caco-2 cell proliferation and DNA synthesis. -
ACCOLATE® (Zafirlukast) TABLETS DESCRIPTION
ACCOLATE® (zafirlukast) TABLETS DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o tolylsulfonylbenzamide. The molecular weight of zafirlukast is 575.7 and the structural formula is: The empirical formula is: C31H33N3O6S Zafirlukast, a fine white to pale yellow amorphous powder, is practically insoluble in water. It is slightly soluble in methanol and freely soluble in tetrahydrofuran, dimethylsulfoxide, and acetone. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium, lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action: Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Patients with asthma were found in one study to be 25 100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and Reference ID: 3407275 inhibited inhaled LTD4-induced influx of eosinophils into animal lungs. Inhalational challenge studies in sensitized sheep showed that zafirlukast suppressed the airway responses to antigen; this included both the early- and late-phase response and the nonspecific hyperresponsiveness. -
Montelukast, a Leukotriene Receptor Antagonist, Reduces the Concentration of Leukotrienes in the Respiratory Tract of Children with Persistent Asthma
Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma Benjamin Volovitz, MD,a,b Elvan Tabachnik, MD,c Moshe Nussinovitch, MD,b Biana Shtaif, MSc,b Hanna Blau, MD,a Irit Gil-Ad, PhD,b Abraham Weizman, MD,b and Itzhak Varsano, MDa,b Petah Tikva, Tel Aviv, and Rehovot, Israel Background: Leukotrienes are bronchoactive mediators secreted by inflammatory cells in the respiratory mucosa on Abbreviations used exposure to asthma triggers. BAL: Bronchoalveolar lavage Objective: We investigated the effect of montelukast, a CysLT1: Cysteinyl leukotriene 1 (receptor) leukotriene receptor antagonist, on the release of leukotrienes ECP: Eosinophilic cationic protein in the respiratory mucosa of children with persistent asthma. LTC4: Leukotriene C4 Method: Twenty-three children aged 6 to 11 years with moder- LTD4: Leukotriene D4 ately severe asthma were treated in a cross-over design start- LTE4: Leukotriene E4 ing, after a 2-week run in period, with either montelukast (n = 12) or cromolyn (n = 11) for 4 weeks with a 2-week washout period between treatments. Twelve of them were then treated Cysteinyl leukotrienes are potent proinflammatory with either montelukast or beclomethasone for 6 months. The mediators produced from a variety of inflammatory use of β -agonists was recorded on a diary card. The concen- 2 cells, including mast cells, eosinophils, basophils and tration of leukotriene C4 (LTC4) was measured by HPLC in nasal washes obtained before and at the end of each treatment macrophages. Leukotriene C4 (LTC4) is metabolized period. Eosinophilic cationic protein (ECP) was measured in enzymatically to leukotriene D4 (LTD4) and subsequent- the nasal washes by RIA. -
Product Information
Product Information Leukotriene B4 Item No. 20110 CAS Registry No.: 71160-24-2 Formal Name: 5S,12R-dihydroxy-6Z,8E,10E,14Z- eicosatetraenoic acid OH OH Synonym: LTB 4 MF: C20H32O4 COOH FW: 336.5 Purity: ≥97%* Stability: ≥1 year at -20°C Supplied as: A solution in ethanol λ ε UV/Vis.: max: 270 nm : 50,000 Miscellaneous: Light Sensitive Laboratory Procedures For long term storage, we suggest that leukotriene B4 (LTB4) be stored as supplied at -20°C. It should be stable for at least one year. LTB4 is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as DMSO or dimethyl formamide purged with an inert gas can be used. LTB4 is miscible in these solvents. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. If an organic solvent-free solution of LTB4 is needed, the ethanol can be evaporated under a stream of nitrogen and the neat oil dissolved in the buffer of choice. LTB4 is soluble in PBS (pH 7.2) at a concentration of 1 mg/ml. Be certain that your buffers are free of oxygen, transition metal ions, and redox active compounds. Also, ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day. 1-3 LTB 4 is a dihydroxy fatty acid derived from arachidonic acid through the 5-lipoxygenase pathway. -
The Nuclear Membrane Organization of Leukotriene Synthesis
The nuclear membrane organization of leukotriene synthesis Asim K. Mandala, Phillip B. Jonesb, Angela M. Baira, Peter Christmasa, Douglas Millerc, Ting-ting D. Yaminc, Douglas Wisniewskic, John Menkec, Jilly F. Evansc, Bradley T. Hymanb, Brian Bacskaib, Mei Chend, David M. Leed, Boris Nikolica, and Roy J. Sobermana,1 aRenal Unit, Massachusetts General Hospital, Building 149-The Navy Yard, 13th Street, Charlestown, MA 02129; bDepartment of Neurology and Alzheimer’s Disease Research Laboratory, Massachusetts General Hospital, Building 114-The Navy Yard, 16th Street, Charlestown MA, 02129; cMerck Research Laboratories, Rahway, NJ 07065; and dDivision of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA 02115 Edited by K. Frank Austen, Brigham and Women’s Hospital, Boston, MA, and approved November 4, 2008 (received for review August 19, 2008) Leukotrienes (LTs) are signaling molecules derived from arachi- sis, whereas in eosinophils and polymorphonuclear leukocytes donic acid that initiate and amplify innate and adaptive immunity. (PMN), a combination of cytokines, G protein-coupled receptor In turn, how their synthesis is organized on the nuclear envelope ligands, or bacterial lipopolysaccaharide perform this function of myeloid cells in response to extracellular signals is not under- (13–15). An emerging theme in cell biology and immunology is that stood. We define the supramolecular architecture of LT synthesis assembly of multiprotein complexes transduces apparently dispar- by identifying the activation-dependent assembly of novel multi- ate signals into a common read-out. We therefore sought to identify protein complexes on the outer and inner nuclear membranes of multiprotein complexes that include 5-LO associated with FLAP mast cells. -
Comparative Protective Effect of Zileuton and MK-886 Against Acute
Scholars LITERATURE La Prensa Medica Argentina Research Article Volume 105 Issue 5 Comparative Protective Effect of Zileuton and MK-886 against Acute Kidney Injury Induced by Doxorubicin Ahmed M Sultan, Hussam H Sahib, Hussein A Saheb* and Bassim I Mohammad College of Pharmacy, University of Al-Qadisiyah, Iraq Abstract Objective: To determine the protective effects of the leukotriene inhibitors MK-886 and Zileuton on doxorubicin (DX)-induced acute kidney damage in a rat model. Methods: A rat model of acute kidney injury (AKI) was established by a 3-day regimen of DX. The animals were suitably treated with MK-866 or Zileuton, and untreated DX injected and healthy controls were also included. The rat sera were analyzed for the levels of creatinine and urea as markers of renal injury and for the levels of the oxidative stress markers GSH and MDA using standard assays. In addition, the renal tissues of the rats were processed and histo-pathologically analyzed by HE staining. Results: DX injection significantly increased the levels of creatinine and urea, indicating dysfunctional kidneys. The levels of both metabolites were restored to baseline levels by MK-866 while Zileuton significantly affected only urea levels. In addition, the GSH levels were significantly decreased and that of MDA was increased upon DX exposure, indicating oxidative damage. While MK-866 treatment significantly reversed the status of both GSH and MDA compared to the DX group, Zileuton had no significant effects on the levels of either. Finally, DX caused extensive renal tissue damage, which was rescued by MK-866 and to a lesser extent by Zileuton. -
Strict Regio-Specificity of Human Epithelial 15-Lipoxygenase-2
Strict Regio-specificity of Human Epithelial 15-Lipoxygenase-2 Delineates its Transcellular Synthesis Potential Abigail R. Green, Shannon Barbour, Thomas Horn, Jose Carlos, Jevgenij A. Raskatov, Theodore R. Holman* Department Chemistry and Biochemistry, University of California Santa Cruz, 1156 High Street, Santa Cruz CA 95064, USA *Corresponding author: Tel: 831-459-5884. Email: [email protected] FUNDING: This work was supported by the NIH NS081180 and GM56062. Abbreviations: LOX, lipoxygenase; h15-LOX-2, human epithelial 15-lipoxygenase-2; h15-LOX-1, human reticulocyte 15-lipoxygenase-1; sLO-1, soybean lipoxygenase-1; 5-LOX, leukocyte 5-lipoxygenase; 12-LOX, human platelet 12-lipoxygenase; GP, glutathione peroxidase; AA, arachidonic acid; HETE, hydoxy-eicosatetraenoic acid; HPETE, hydroperoxy-eicosatetraenoic acid; diHETEs, dihydroxy-eicosatetraenoic acids; 5-HETE, 5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5-HPETE, 5-hydro peroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; 12-HPETE, 12-hydroperoxy-5Z,8Z,10E, 14Z-eicosatetraenoic acid; 15-HPETE, 15-hydroperoxy-5Z,8Z,10Z,13E- eicosatetraenoic acid; 5,15-HETE, 5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic acid; 5,15-diHPETE, 5,15-dihydroperoxy-6E,8Z,10Z,13E-eicosatetraenoic acid; 5,6- diHETE, 5S,6R-dihydroxy-7E,9E,11Z,14Z-eicosatetraenoic acid; LTA4, 5S-trans-5,6- oxido-7E,9E,11Z,14Z-eicosatetraenoic acid; LTB4, 5S,12R-dihydroxy-6Z,8E,10E,14Z- eicosatetraenoic acid; LipoxinA4 (LxA4), 5S,6R,15S-trihydroxy-7E,9E,11Z,13E- eicosatetraenoic acid; LipoxinB4 (LxB4), 5S,14R,15S-trihydroxy-6E,8Z,10E,12E- eicosatetraenoic acid. Abstract Lipoxins are an important class of lipid mediators that induce the resolution of inflammation, and arise from transcellular exchange of arachidonic acid (AA)- derived lipoxygenase products. -
Development of Multitarget Agents Possessing Soluble Epoxide Hydrolase Inhibitory Activity T
Prostaglandins and Other Lipid Mediators 140 (2019) 31–39 Contents lists available at ScienceDirect Prostaglandins and Other Lipid Mediators journal homepage: www.elsevier.com/locate/prostaglandins Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity T Kerstin Hiesingera, Karen M. Wagnerb, Bruce D. Hammockb, Ewgenij Proschaka, ⁎ Sung Hee Hwangb, a Institute of Pharmaceutical Chemistry, Goethe-University of Frankfurt, Max-von-Laue Str. 9, D-60439, Frankfurt am Main, Germany b Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA ARTICLE INFO ABSTRACT Keywords: Over the last two decades polypharmacology has emerged as a new paradigm in drug discovery, even though Polypharmacology developing drugs with high potency and selectivity toward a single biological target is still a major strategy. Multitarget agents Often, targeting only a single enzyme or receptor shows lack of efficacy. High levels of inhibitor of a single Dual inhibitors/modulators target also can lead to adverse side effects. A second target may offer additive or synergistic effects to affecting Soluble epoxide hydrolase the first target thereby reducing on- and off-target side effects. Therefore, drugs that inhibit multiple targets may offer a great potential for increased efficacy and reduced the adverse effects. In this review we summarize recent findings of rationally designed multitarget compounds that are aimed to improve efficacy and safety profiles compared to those that target a single enzyme or receptor. We focus on dual inhibitors/modulators that target the soluble epoxide hydrolase (sEH) as a common part of their design to take advantage of the beneficial effects of sEH inhibition. -
Supplementary Information Optimization of a Method For
Supplementary Information Optimization of a method for the simultaneous extraction of polar and non-polar oxylipin metabolites, DNA, RNA, small RNA, and protein from a single small tissue sample Yu Hasegawa, Yurika Otoki, Shannon McClorry, Laurynne C. Coates, Rachel L. Lombardi, Ameer Y. Taha, Carolyn M. Slupsky Procedure for Methods A and B For Methods A and B, the following steps were modified: 3.1. Preparation of Reagents 1. Prepare chloroform:methanol (2:1) with 0.002% BHT [Solution 1]. Pre-chill in a -20 °C freezer. 2. Prepare 1 mM EDTA dissolved in Type I water [Solution 2]. Pre-chill to 4 °C. 3. Prepare chloroform:methanol (10:1) [Solution 3]. Pre-chill in a -20 °C freezer. 3.3. Metabolite Extraction 3.3.1. Method A 1. Add 1600 µL of chloroform, 800 µL of methanol, and 600 µL of Type I ultrapure water to tubes with ground brain tissue and mix by vortexing for 20 seconds. 2. Centrifuge the tubes for 15 min at 2,000 rpm at 0 °C to separate the sample into three layers. 3. Collect the upper layer into a new 15 mL conical centrifuge tube. Do not disturb the cell layer. Keep the tube on ice and proceed to step 22. 4. Using a 9-inch glass Pasteur pipette, collect the bottom layer and place in a new 8 mL glass tube. Place the tube on ice and proceed to step 31. 5. Proceed to step 42 to process the middle layer. 3.3.2. Method B 1. Add 2.4 mL of cold Solution 1 into the 8 mL glass tube with the cryoground tissue. -
Leukotriene Receptors (Leukotriene B4 Receptor/Chemotaxis/W Oxidation/Autocoid) ROBERT M
Proc. Nail. Acad. Sci. USA Vol. 81, pp. 5729-5733, September 1984 Cell Biology Oxidation of leukotrienes at the w end: Demonstration of a receptor for the 20-hydroxy derivative of leukotriene B4 on human neutrophils and implications for the analysis of leukotriene receptors (leukotriene B4 receptor/chemotaxis/w oxidation/autocoid) ROBERT M. CLANCY, CLEMENS A. DAHINDEN, AND TONY E. HUGLI Department of Immunology, Scripps Clinic and Research Foundation, La Jolla, CA 92037 Communicated by Hans J. Muller-Eberhard, May 4, 1984 ABSTRACT Leukotriene B4 [LTB4; (5S,12R)-5,12-dihy- with an ED50 of 10 nM (4-6). The LTB4-hPMN interaction is droxy-6,14-cis-8,10-trans-icosatetraenoic acid] and its 20- highly stereospecific. For example, the isomer 6-trans- hydroxy derivative [20-OH-LTB4; (5S,12R)-5,12,20-trihy- LTB4, which differs structurally from LTB4 only in the con- droxy-6,14-cis-8,10-trans-icosatetraenoic acid] are principal figuration at the C-6 double bond, is a weaker chemoattrac- metabolites produced when human neutrophils (hPMNs) are tant than LTB4 by 3 orders of magnitude, and none of the stimulated by the calcium ionophore A23187. These com- other 5,12-dihydroxyicosatetraenoic acid (5,12-diHETE) pounds were purified to homogeneity by Nucleosil C18 and si- isomers display significant chemotactic activity (6). Because licic acid HPLC and identified by UV absorption and gas chro- LTB4 is a potent and stereospecific chemoattractant, char- matographic/mass spectral analyses. 20-OH-LTB4 is consider- acterization of the LTB4 receptor should be possible using ably more polar than LTB4 and interacts weakly with the direct ligand binding. -
Intrinsic 5-Lipoxygenase Activity Is Required for Neutrophil Responsivity
Proc. Natl. Acad. Sci. USA Vol. 91, pp. 8156-8159, August 1994 Cell Biology Intrinsic 5-lipoxygenase activity is required for neutrophil responsivity DAVID M. GUIDOT, MICHAEL J. REPINE, JAY Y. WESTCOTT, AND JOHN E. REPINE Webb-Waring Institute for Biomedical Research and Department of Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Box C-321, Denver, CO 80262 Communicated by David W. Talmage, May 6, 1994 (receivedfor review March 9, 1994) ABSTRACT We found that intrinsic neutrophil 5-lipoxy- neutrophil-mediated injury in isolated lungs given IL-8 intra- genase activity was necessary for human neutrophil adherence tracheally. and chemotaxis in viro and human neutrophil-mediated acute edematous injury in isolated perfused rat lungs given interleu- kin 8 intratracheally. Treatment with either Zileuton (a specific MATERIALS AND METHODS reversible competitive inhibitor of 5-lipoxygenase) or MK886 Purification of Human Neutrophils. Heparinized blood was (a specific irreversible inhibitor ofthe 5-lipoxygenase activator obtained from healthy volunteers. Neutrophils were isolated protein) prevented stimulated neutrophil adherence and by using a Percoll gradient and differential centrifugation. chemotaxis (but not superoxide anion production) in vitro. Each preparation contained highly purified (>99%o) neutro- Zileuton- or MK886-inhibited neutrophil chemotaxis was not phils that were suspended in Hanks' balanced salt solution restored by adding leukotriene B4 in vitro. Perfusion with (Sigma) at a concentration of -
Inflammation, Cancer and Oxidative Lipoxygenase Activity Are Intimately Linked
Cancers 2014, 6, 1500-1521; doi:10.3390/cancers6031500 OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Review Inflammation, Cancer and Oxidative Lipoxygenase Activity are Intimately Linked Rosalina Wisastra and Frank J. Dekker * Pharmaceutical Gene Modulation, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +31-5-3638030; Fax: +31-5-3637953. Received: 16 April 2014; in revised form: 27 June 2014 / Accepted: 2 July 2014 / Published: 17 July 2014 Abstract: Cancer and inflammation are intimately linked due to specific oxidative processes in the tumor microenvironment. Lipoxygenases are a versatile class of oxidative enzymes involved in arachidonic acid metabolism. An increasing number of arachidonic acid metabolites is being discovered and apart from their classically recognized pro-inflammatory effects, anti-inflammatory effects are also being described in recent years. Interestingly, these lipid mediators are involved in activation of pro-inflammatory signal transduction pathways such as the nuclear factor κB (NF-κB) pathway, which illustrates the intimate link between lipid signaling and transcription factor activation. The identification of the role of arachidonic acid metabolites in several inflammatory diseases led to a significant drug discovery effort around arachidonic acid metabolizing enzymes. However, to date success in this area has been limited. This might be attributed to the lack of selectivity of the developed inhibitors and to a lack of detailed understanding of the functional roles of arachidonic acid metabolites in inflammatory responses and cancer.